Back to top
more

Sanofi (SNY)

(Real Time Quote from BATS)

$51.64 USD

51.64
2,504,637

-1.21 (-2.29%)

Updated Nov 6, 2024 03:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus

by Zacks Equity Research

Denali (DNLI) Q1 loss narrows year over year due to lower expenses despite nil revenues.

Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

Kymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the current cash balance to provide a runway into the first half of 2027.

Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales

by Zacks Equity Research

Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.

Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?

by Zacks Equity Research

An increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided Regeneron (REGN) in partially offsetting the decline in Eylea sales.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates

by Kinjel Shah

Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.

AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up

by Zacks Equity Research

AstraZeneca (AZN) beats first-quarter estimates for earnings and sales, driven by increased demand for its key oncology and rare disease drugs.

Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up

by Zacks Equity Research

Sanofi (SNY) posts first-quarter 2024 results and maintains the earnings growth guidance for the year.

Ahan Chakraborty headshot

What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?

by Ahan Chakraborty

Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.

Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study

by Zacks Equity Research

Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.

AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect

by Zacks Equity Research

Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.

Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study

by Zacks Equity Research

Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.

Pfizer's (PFE) RSV Vaccine Study in Adults Under 60 Meets Goal

by Zacks Equity Research

Pfizer's (PFE) RSV vaccine, Abrysvo, generates an immune response in a phase III study evaluating it in higher-risk adults aged 18 to 59, non-inferior to that in older adults.

Regeneron (REGN) Gets FDA Nod for Praluent Label Extension

by Zacks Equity Research

Regeneron (REGN) obtains FDA approval for Praluent as an adjunct to diet and other LDL-C, lowering therapies to include pediatric patients aged eight and older with HeFH.

ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study

by Zacks Equity Research

ASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with eczema, who have previously been treated with Dupixent but did not achieve an adequate response.

J&J (JNJ) Seeks Expanded Use of Tremfya for Ulcerative Colitis

by Zacks Equity Research

Tremfya is an important drug in J&J's (JNJ) immunology drugs portfolio and a key driver of top-line growth.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Priority Tag to SNY, ABBV Filings, CHMP Nod for AZN, JNJ, MRK

by Kinjel Shah

The FDA grants priority review status to Sanofi's (SNY) and AbbVie's (ABBV) sBLAs for Dupixent and Epkinly, respectively

Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up

by Zacks Equity Research

Denali (DNLI) reports lower than expected fourth-quarter financial results. The stock, however, rises 38% on news of funding raised by the company, which is expected to strengthen its cash position.

BioMarin (BMRN) Posts Q4 Earnings Beat, Upbeat Voxzogo Sales

by Zacks Equity Research

BioMarin (BMRN) reports encouraging fourth-quarter results, with earnings and sales beating estimates. The rapid uptake of Voxzogo boosts revenues.

Mark Vickery headshot

Top Analyst Reports for Microsoft, Amazon.com & Berkshire Hathaway

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Amazon.com, Inc. (AMZN) and Berkshire Hathaway Inc. (BRK.B).

AstraZeneca (AZN) Q4 Earnings & Sales Miss Estimates, Stock Down

by Zacks Equity Research

AstraZeneca (AZN) marginally misses fourth-quarter estimates for earnings and sales. It expects revenues and EPS to increase at a low double-digit to low teens percentage in 2024 at CER.

AstraZeneca (AZN) to Report Q4 Earnings: Here's What to Expect

by Zacks Equity Research

Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.

Regeneron (REGN) Q4 Earnings & Sales Top, Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) beats earnings and sales estimates in fourth-quarter 2023, fueled by Dupixent. However, sales of the lead drug, Eylea, continue to fall.

Kinjel Shah headshot

Pharma Stock Roundup: PFE, MRK, NVO & SNY's Q4 Earnings, FDA Updates

by Kinjel Shah

Pfizer (PFE), Merck (MRK), Novartis (NVS), Novo Nordisk (NVO) and Sanofi (SNY) announce fourth-quarter and full-year 2023 results.

TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up

by Zacks Equity Research

TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.

Sanofi (SNY) Misses on Q4 Earnings and Sales, Stock Down

by Zacks Equity Research

Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. It maintains 2024 earnings growth guidance.